

phosphatase (ACP), β -hexosaminidase, and α -mannosidase, an increase in the level of the LSD marker in the subject relative to the corresponding level of the LSD marker in a non-affected individual or population being indicative of a LSD.

53. Cancel

56. Cancel

57. Cancel

66. The method according to claim 52, wherein the step of assaying the level of a LSD marker comprises contacting the biological sample with one or more antibodies specific for said LSD marker for a time and under conditions sufficient for the formulation of a complex to occur.

67. Cancel

68. The method according to claim 67, wherein the one or more antibodies are monoclonal antibodies.

69. The method according to claim 66, wherein the one or more antibodies is/are labeled with a reporter molecule.

70. The method according to claim 66, further comprising the step of contacting a complex formed between the LSD marker and one of the one or more antibodies with a labeled antibody for a time and under conditions sufficient for binding to occur.

71. The method according to claim 70, wherein the labeled antibody is labeled with a reporter molecule.

74. The method according to claim 52, wherein:

- (a) the LSD is selected from the list set forth in Table 1;
- (b) the LSD marker is LAMP-1;
- (c) the biological sample comprises blood, serum or urine; and
- (d) the assay comprises measuring the enzymatic activity of the LSD

marker or is an immunoassay.